Results 11 to 20 of about 4,245 (206)

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review [PDF]

EJNMMI Research, 2018
Background The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation.
Daphne Merel Valerie Huizing, Berlinda Jantina de Wit-van der Veen, Marcel Verheij, Marcellus Petrus Maria Stokkel   +3 more
doaj   +3 more sources

Lutathera^®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Pharmaceuticals, 2019
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.
Ute Hennrich, Klaus Kopka
doaj   +2 more sources

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Cancer Medicine, 2021
Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors.
Marianne S. Elston, Amanda Love, Dev Kevat, Richard Carroll, Zhen Rong Siow, Sharon Pattison, Veronica Boyle, Eva Segelov, Andrew H. Strickland, David Wyld, Richard Gauci, Kim Kennedy, David Ransom, the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)   +13 more
doaj   +2 more sources

Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer [PDF]

Case Reports in Oncology, 2019
The field of theranostics is a new nuclear medicine tool being utilized in the treatment of different types of cancers. It couples receptor-specific based imaging predicting and guiding response to receptor-specific based radionuclide therapies.
Pashtoon M. Kasi, Akash Sharma, Manoj K. Jain   +2 more
doaj   +2 more sources

RADIONUCLIDE IMAGING AND THERAPY OF NEUROENDOCRINE TUMOURS

Journal of Cancer and Allied Specialties, 2015
The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise. Although NETs are a heterogeneous group of tumours, they have some similar properties, for example, that they can concentrate neuroamines and tend to have a high degree of ...
Shaunak Navalkissoor, Gopinath Gnanasegaran   +1 more
doaj   +3 more sources

Effect of Peptide Receptor Radionuclide Therapy in Combination with Temozolomide against Tumor Angiogenesis in a Glioblastoma Model [PDF]

, 2021
Cell adhesion receptor integrin αvβ3 is a promising biomarker for developing tumor-angiogenesis targeted theranostics. In this study, we aimed to examine the therapeutic potential of peptide receptor radionuclide therapy (PRRT) with 188Re-IDA-D-[c(RGDfK)]
In Ho Song, Nunzio Denora, Hyun Soo Park, Byung Chul Lee, Sang Eun Kim, Ji Young Choi, Sang Hee Lee, Jae Ho Jung, Francesco Leonetti   +8 more
core   +2 more sources

Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT

Current Oncology, 2021
Peptide receptor radionuclide therapy (PRRT) is used to treat patients with advanced malignant pheochromocytomas (PCCs) and paragangliomas (PGLs).
Erica S. Tsang, Gayle Funk, Janet Leung, Grace Kalish, Hagen F. Kennecke   +4 more
doaj   +1 more source

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

Clinical and Translational Radiation Oncology, 2020
Background: The combination of somatostatin receptor-directed peptide receptor radionuclide therapy (PRRT) in combination with external beam radiotherapy (EBRT) might prove a feasible treatment option in patients with advanced meningioma.
Philipp E. Hartrampf, Heribert Hänscheid, Olivia Kertels, Andreas Schirbel, Michael C. Kreissl, Michael Flentje, Reinhart A. Sweeney, Andreas K. Buck, Bülent Polat, Constantin Lapa   +9 more
doaj   +1 more source

Peptide receptor radionuclide therapy with177lu-dotatate in a case of concurrent neuroendocrine tumors and meningioma: Achieving two things in a single action [Eşzamanlı nöroendokrin tümör ve menenjiyom olgusunda177lu-dotatate ile peptid reseptör radyonüklid tedavisi: Tek bir uygulama ile iki hastalığın tedavisi]

, 2021
We present a partial response of peptide receptor radionuclide therapy (PRRT) with177Lu-DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma.
Nabipour, I, Rekabpour, S.J, Gholamrezanezhad, A, Jafari, E, Amini, A, Dadgar, H, Nemati, R, Ahmadzadehfar, H, Assadi, M   +8 more
core   +1 more source

Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics

Xiehe Yixue Zazhi, 2022
Peptide receptor radionuclide therapy (PRRT) specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells that overexpress specific receptors.
LIU Qingxing, CHEN Xiaoyuan, ZHU Zhaohui
doaj   +1 more source